Orforglipron for peripheral artery disease with leg pain
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a new oral medication called orforglipron to see if it can improve walking distance in people with peripheral artery disease (PAD) who have leg pain when walking. It may be a good option if you have PAD and your walking is limited by leg cramping, not other health issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have leg pain or cramping when walking that goes away with rest (called intermittent claudication).
- You have had an ankle-brachial index (ABI) test that is 0.9 or less.
- Your body mass index (BMI) is at least 23.
- If you have diabetes, your hemoglobin A1c (HbA1c) must be 10% or lower.
- Your walking ability is not limited by other conditions like arthritis or severe breathing problems.
- You have not had certain heart or blood vessel procedures or events in the last 60 days (like a stroke, heart attack, or stent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized exercise program for people with peripheral arterial disease (PAD), a condition that causes leg pain when walking. The goal is to see if a tailored exercise plan can help reduce pain, improve walking distance, and boost quality of life.
This study tests an investigational drug called etrinabdione for people with peripheral arterial disease (reduced blood flow to the legs) and type 2 diabetes. The goal is to see if it is safe, tolerable, and might help improve leg pain or walking ability.
This trial tests a supervised exercise program for people with leg pain when walking caused by narrowed leg arteries. The goal is to see if exercise can improve walking ability and quality of life.
This trial tests whether a drug called diroximel fumarate (Vumerity) can improve blood flow and walking ability in people with peripheral artery disease (PAD). It compares people with PAD to healthy volunteers of the same age.
This study tests whether ramipril (a blood-pressure medicine) can improve leg muscle problems linked to poor blood flow in people with chronic claudication—pain that limits walking. It’s mainly looking at changes related to oxidative stress and muscle scarring (fibrosis).
This study is testing a special exercise and lifestyle program (called cardiac rehabilitation) for people with peripheral artery disease. The program may help improve your walking ability and reduce leg pain, so you can do daily activities more easily.
Hear when a new Peripheral Arterial Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.